Building a better future through collaboration and innovation
Nodus Oncology's ambitious vision is led by a group of entrepreneurial scientists, whose mission is to deliver new treatment options to patients.
Executive team
Scientific pioneers and strategic leaders driving Nodus Oncology's ambitious drug development.
Research scientist bringing wide-ranging experience in drug discovery, DDR mechanisms, apoptosis, and mitochondrial biology.
Entrepreneurial financial strategist with extensive experience of financial modelling and business management, deal negotiation and investor relations.
Seasoned professional with experience in drug discovery, life science venture capital, and as a Business Development and Investment Director in UK oncology biotech. Proven expertise in addressing therapy challenges and accelerating patient access to treatments. Industry network builder.
(Program Management)
Experienced in academia, pharma, and CROs, specialising in oncology and immunology research. Skilled in managing early-stage preclinical projects, with expertise in novel immuno-oncology targets to redirect the immune system against tumours.
Board of Directors
Nodus Oncology's strategic direction is aided by a team of seasoned entrepreneurs with extensive, multimodal experience in company growth and development, spanning all phases of drug discovery.
Experienced Non-Executive Director and Chairperson with a broad scientific background and a wealth of experience in both industry and the public sector.
Seasoned Biotech executive and board member with fundraising experience.
Senior Executive and entrepreneur with the vision, drive and experience of successful oncology drug development and company exits to lead the company forward. Company builder.
Co-founder of KHAN Technology Transfer Fund, and Managing Director and CSO of the Lead Discovery Center.
Scientific Advisory Board
The experts guiding our advancements in DDR-targeting therapies.
Senior scientist at BiOrigin, Denmark and former Associate Professor at the University of Copenhagen, with extensive in-depth expertise of the DDR field.
Professor of Molecular Oncology in the Department of Medical Oncology at the University of Groningen, The Netherlands.
Head of Screening and Assay Development at the Lead Discovery Center in Dortmund, Germany.
Professor of Genome Stability at the University of Sussex, UK.
